Allogene Therapeutics is a clinical-stage immunology company developing off-the-shelf CAR T cell treatments using genetic engineering and cell manufacturing techniques for cancer and autoimmune conditions. The company's pipeline includes cemacabtagene ansegedleucel, designed to treat large B-cell lymphoma by targeting the CD19 protein; ALLO-316, which targets CD70 for renal cell carcinoma; and ALLO-329, a dual-targeting candidate intended for autoimmune diseases including lupus and related inflammatory conditions. Founded in 2017 and based in South San Francisco, the company uses proprietary technology to manufacture these engineered cellular therapies.
1Y: 1.17 (-3.5%) · range 1.05–3.06
entry readiness 82 · STRONG SETUP · exit proximity 0
Value area 1.68–2.19 · 100% of 120d volume overhead · heavy supply
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -17.31% | +7.21% | mature |
| 40d | -37.98% | +7.21% | mature |